Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Slides:

Advertisements

Similar presentations

Ann Intern Med. 2015;162(1): doi: /M Figure Legend:

Advertisements

Volume 79, Issue 11, Pages (June 2011)

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Figure 1 Pathological features of lupus nephritis subtypes

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification

Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E

Quiz Page February 2016 American Journal of Kidney Diseases

Quiz Page December 2007 American Journal of Kidney Diseases

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Jia-Jung Lee, MD, Hung-Chun Chen, MD, PhD

C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu

Volume 77, Issue 9, Pages (May 2010)

The clinical spectrum of tubulointerstitial nephritis

Quiz Page December 2008 American Journal of Kidney Diseases

Volume 75, Issue 12, Pages (June 2009)

Lupus Nephritis: Mesangial and Membranous Forms (WHO II and V)

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Lupus Nephritis: Proliferative Forms (WHO III, IV)

Association of AIM2, RIG‐I and NLRP3 inflammasomes with better survival in NPC patients.A.Overexpression of ASC, caspase‐1 and IL‐1β proteins as well as.

Volume 95, Issue 3, Pages (March 2019)

Local macrophage proliferation in human glomerulonephritis

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Association of pretreatment interferon (IFN) signature metric (ISM) status with serum autoantibodies, BAFF levels and type I IFN bioactivity. Association.

Volume 71, Issue 7, Pages (April 2007)

The Case | Idiopathic hypocomplementemic interstitial nephritis

Crystals in podocytes: an unusual manifestation of systemic disease

Volume 62, Issue 2, Pages (August 2002)

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Crescentic Glomerulonephritis Associated With Hypocomplementemic Urticarial Vasculitis Syndrome Leah Balsam, MD, Mohammed Karim, MD, Frederick Miller,

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis Gary S. Hill, Michel Delahousse,

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Volume 69, Issue 10, Pages (May 2006)

No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Quiz Page June 2009 American Journal of Kidney Diseases

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Volume 73, Issue 5, Pages (March 2008)

Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.

Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E

The effect of purified IgG from healthy controls or patients with lupus nephritis on tyrosine phosphorylation in podocytes at two different IgG concentrations.

Serum proteins dysregulated at baseline in patients enrolled in the MUSE study subsetted by IFNGS test status, Cutaneous Lupus Erythematosus Disease Area.

Tyrosine phosphorylation of proteins in podocyte lysates following exposure to healthy or lupus nephritis plasma. Tyrosine phosphorylation of proteins.

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.

Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone.

Representative example of gating on T-cell subpopulations.

Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.

Immune cell populations associated with type I IFNGS test status and disease activity. Immune cell populations associated with type I IFNGS test status.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

(A) Photomicrograph depicting typical appearance of a glomerulus in patient with mesangial type lupus nephritis, WHO class II. (Periodic acid-Schiff stain;

Overall gene expression in monocyte subsets in patients and controls.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Collapsing glomerulopathy (CG) and lesions that may resemble CG histologically in renal biopsies from patients with systemic lupus erythematosus. Collapsing.

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.

Overall and recurrence-free survival.

(A–E) demonstrate a kidney biopsy from a patient with lupus nephritis (LN) class V. Representative micrographs: (A), an inflammatory infiltrate with T.

Presentation transcript:

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue. Immunohistochemistry staining of interferon (IFN)-λ in renal tissue. The figure demonstrates a kidney biopsy from a patient with lupus nephritis class IV. The representative micrograph displays IFNλ staining predominantly found in tubular cells and in an incipient cellular crescent in the glomeruli. In the glomeruli without crescent, the staining is sparse. Original magnifications: ×20. Agneta Zickert et al. Lupus Sci Med 2016;3:e000170 ©2016 by Lupus Foundation of America